ロード中...
Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects
BACKGROUND. Individuals treated with the cholesteryl ester transfer protein (CETP) inhibitor anacetrapib exhibit a reduction in both LDL cholesterol and apolipoprotein B (ApoB) in response to monotherapy or combination therapy with a statin. It is not clear how anacetrapib exerts these effects; ther...
保存先:
出版年: | J Clin Invest |
---|---|
主要な著者: | , , , , , , , , , , , , , , , , , , , , |
フォーマット: | Artigo |
言語: | Inglês |
出版事項: |
American Society for Clinical Investigation
2015
|
主題: | |
オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4497759/ https://ncbi.nlm.nih.gov/pubmed/25961461 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI80025 |
タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|